Business Context and Reporting Period
This Form 8-K is filed by Gemphire Therapeutics Inc. (not Metavia Inc.) on March 15, 2019. The report serves to furnish the press release detailing financial results for the fourth quarter and the full year ended December 31, 2018. The registrant is identified as an emerging growth company.
Key Financial Metrics
The provided filing text acts as a cover document and does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within Exhibit 99.1 (the Press Release), which is incorporated by reference but not included in the input text.
Material Changes
The filing text does not provide specific data regarding material changes versus prior periods. It only confirms the issuance of results for the Q4 and full-year 2018 period.
Guidance, Outlook, and Risks
The text does not include management commentary, forward-looking guidance, specific risk factors, or details on contingencies. It notes that the information is furnished pursuant to Item 2.02 and is not deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Gemphire Therapeutics Inc., as the input metadata incorrectly listed "Metavia Inc."
- Locate and review Exhibit 99.1 (Press Release dated March 15, 2019) to obtain actual financial figures for Q4 and FY 2018.
- Confirm the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 liability standards.